Beranda › Kanker (semua jenis) › Nebraska › Lincoln
Uji klinis Kanker (semua jenis) di Lincoln, NE
3 studi untuk Kanker (semua jenis) mencari peserta di lokasi sekitar Lincoln (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 2/3
- Nho - Revive Research Institute /ID# 277569, Lincoln
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 1
- NHO Revive Research Institute, LLC /ID# 267869, Lincoln
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 2/3
- Nho - Revive Research Institute /ID# 276115, Lincoln
Uji klinis Kanker (semua jenis) di kota lain
- Houston, TX121 studi
- New York City, NY110 studi
- Boston, MA86 studi
- Los Angeles, CA73 studi
- Nashville, TN65 studi
- Philadelphia, PA59 studi
- Durham, NC58 studi
- Washington, DC58 studi
- Chicago, IL51 studi
- Seattle, WA49 studi
- Atlanta, GA49 studi
- Arlington, VA48 studi
Studi lain di Lincoln
- Kanker Paru Non-Sel Kecil16 studi
- Gagal Jantung8 studi
- Kanker Paru7 studi
- Penyakit Arteri Koroner5 studi
- Kanker Payudara4 studi
- Obesitas4 studi
- Skizofrenia4 studi
- Kanker Kolorektal4 studi
- Mieloma Multipel3 studi
- Melanoma3 studi
- Sklerosis Lateral Amiotrofik3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.